this will rocket - any moment now, page-3

too expensive now, i brought at 1.50 so it doesnt matter.
Consider switching over to PSD or SPL for exposure in nanotechmedicine (higher risk higher returns).

Recent article comparing PSD with Sirtex in the brachytherapy field

We believe PSD’s technological base has wider application
over that of Sirtex’s by virtue of the chemical and physical
properties exhibited by BioSilicon.

PSD has built up an impressive IP portfolio around the use
of nano-structured BioSilicon in numerous biotechnological
applications.

BioSilicon, as a biomaterial is an extremely simple solution
to numerous problems and as such has highly diverse
applications.

The major markets that PSD is expected to focus on are
drug delivery and brachytherapy, the fastest growing
markets in this sector of the industry.

PSD and Qinetiq own over 87% of PsiMedica, giving PSD
access to some of the best scientists in the field at Qinetiq.
Qinetiq is also associated with the Carlyle Group, a preeminent
venture capital company.

We expect the company to sell off non-core technology,
which includes applications in orthopaedics, tissue
engineering, and flexible silicon.

The company needs to sign a collaboration deal with a
major pharmaceutical company to validate its technology.

We believe management is involved in negotiations with a
number of companies.

We also believe that there is an above average chance of PSD’s technology
reaching the market. BioSilicon has been proven to be
clinically safe, and many of the active ingredients being
tested in applications (ranging from drug-delivery to
brachytherapy) are either generic drugs, or have already
been proven to be clinically safe."